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ABSTRACT
Apoptosis is essential for the maintenance of inher-
ited genomic integrity. During DNA damage-induced
apoptosis, mechanisms of cell survival, such as
DNA repair are inactivated to allow cell death to
proceed. Here, we describe a role for the mamma-
lian DNA repair enzyme Exonuclease 1 (Exo1) in DNA
damage-induced apoptosis. Depletion of Exo1 in
human fibroblasts, or mouse embryonic fibroblasts
led to a delay in DNA damage-induced apoptosis.
Furthermore, we show that Exo1 acts upstream of
caspase-3, DNA fragmentation and cytochrome c
release. In addition, induction of apoptosis with
DNA-damaging agents led to cleavage of both iso-
forms of Exo1. The cleavage of Exo1 was mapped to
Asp514, and shown to be mediated by caspase-3.
Expression of a caspase-3 cleavage site mutant
form of Exo1, Asp514Ala, prevented formation of
the previously observed fragment without any
affect on the onset of apoptosis. We conclude that
Exo1 has a role in the timely induction of apoptosis
and that it is subsequently cleaved and degraded
during apoptosis, potentially inhibiting DNA
damage repair.
INTRODUCTION
DNA is constantly damaged by endogenous factors (e.g.
free radicals generated during normal cellular metabolism)
and exogenous factors [e.g. ultraviolet (UV) light]. In
order for genomic stability to be maintained, it is essential
that this damage is repaired. The repair of DNA damage
involves a highly coordinated series of events: ﬁrst, the cell
must signal to halt cell cycle progression at precise cell
cycle checkpoints, following this, DNA damage-speciﬁc
repair pathways are activated (1). These pathways lead
to repair of the damaged DNA and their composition is
dependant on the type of damage. Following repair, cell
cycle checkpoints are released and the cell cycle can
progress normally. However large amounts of DNA
damage can trigger another pathway called apoptosis,
this initiates signals which ultimately result in controlled
cell death. Apoptosis is essential for the removal of
damaged cells, which would have the potential to carry
deleterious mutations onto daughter cells. If such cells
were allowed to continue dividing in an organism, this
could potentially lead to tumour development (1).
Caspases are the major proteases involved in apoptosis.
This family of proteins contribute to cellular disintegra-
tion via targeted cleavage of a collection of proteins
involved in many processes within the cell, including
DNA repair and checkpoint activation (2). Of the proteins
in the caspase family, caspase-3, caspase-6 and caspase-7
have been shown to be the major eﬀector caspases in
apoptosis (3). In order to completely understand the role
of caspases in apoptosis, it is essential to identify their
downstream targets. The cleavage of proteins by caspases
is not a random event and appears to target proteins
involved in maintenance of cellular integrity in a highly
speciﬁc manner. Caspases do not completely degrade their
targets, but rather cleave proteins at a few speciﬁc sites.
In general, caspase substrates become inactivated upon
cleavage, however, a subset become activated (4) and con-
tribute to apoptosis. A comprehensive list of caspase sub-
strates can be found on the CASBAH web site (http://
www.casbah.ie). The major apoptotic nuclease Caspase-
activated DNase (CAD) is cleaved by caspase-3 during
apoptosis, this results in the translocation of CAD into
the nucleus and induction of CAD-mediated DNA frag-
mentation (5,6). Two major kinases involved in DNA
damage signalling events; Ataxia Telangiectasia mutated
(ATM) (7) and the catalytic subunit of DNA-dependent
protein kinase (DNA-PK) (8) are also cleaved by caspase-
3 during apoptosis. Cleavage of these two proteins is sug-
gested to prevent DNA repair during apoptosis.
Interestingly, ATM is also required to induce apoptosis
in response to some DNA-damaging agents (9).
The present study provides support for a role for the
DNA damage repair nuclease Exonuclease 1 (Exo1) in the
induction of apoptosis. Exo1 was ﬁrst identiﬁed as a
nuclease required for meiosis in ﬁssion yeast (10).
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possesses 50-30 nuclease activity and 50-ﬂap endonuclease
activity (11,12). There are two isoforms of Exo1 (a and b),
which result from alternate splicing. The isoforms diﬀer at
the C-terminus, with Exo1b having an additional 48
amino acids. Several proteins involved in replication and
DNA repair including PCNA and mismatch repair
(MMR) proteins interact with Exo1 (13). Exo1 has a
role in several DNA repair pathways including MMR,
post-replication repair, meiotic and mitotic recombination
(14–16). Many DNA repair proteins have been implicated
in tumourigenesis, for example mutations in MLH1, an
essential component of MMR are linked to colorectal
cancer (17). The involvement of Exo1 in DNA repair
pathways including MMR suggests it may also be a
target for mutation in tumourigenesis. Consistent with
this, Exo1 deﬁcient mice display a cancer-prone pheno-
type, including increased susceptibility to lymphoma
development (18). In addition, germ-line variants of
Exo1, which aﬀect nuclease function and MMR protein
interactions have been detected in patients with atypical
human non-polyposis colon cancer and other forms of
colorectal cancer (19,20).
In this study, we show that DNA damage-induced
apoptosis is defective in cells depleted of Exo1, suggesting
that Exo1 is required for the timely induction of apopto-
sis. In addition, we show that both Exo1a and Exo1b are
cleaved during apoptosis induced by ultra-violet C (UVC)
and etoposide (ETOP). Caspase-3 is shown to be the pro-
tease responsible for Exo1b cleavage at a speciﬁc site. We
conclude that Exo1 plays a signiﬁcant role in the induction
of apoptosis and that the lack of apoptosis observed in
Exo1-deﬁcient cells may have signiﬁcant implications for
chemotherapy in cancer patients.
MATERIALS AND METHODS
Reagents, antibodies and cell lines
All cell lines were grown in DMEM supplemented with
10% FCS. Antibodies used were as follows: mouse anti-
Flag M2 antibody (Sigma); mouse anti-PARP1 (Zymed);
rabbit anti-caspase-3 (Biosource); rabbit anti-g-tubulin
and mouse anti-b-actin (Sigma); rabbit anti-GFP
(Molecular Probes); rabbit anti-Chk1 S317 and rabbit
anti-p53 S15 (Cell Signalling); goat anti-ATR and
goat anti-Exo1 (Santa Cruz). The recombinant caspase-3
and caspase inhibitor, ZVAD-FMK were supplied by
Biosource. Exo1-deﬁcient and wild-type mouse embryonic
ﬁbroblasts (MEFs) have been described previously (21).
Cloning, site-directed mutagenesis and expression of
Exo1 constructs
A full length Exo1b clone was purchased from Origene.
The full length Exo1b, and fragment of Exo1 encoding
amino acids 1–514 were cloned into the ECOR-V and
BamHI sites of the Flag-2 plasmid (Fermentas). Full
length Exo1b was cloned into the SalI and BamHI sites
of pEGFP-C1 (Clontech). Flag-Exo1b was mutated via
site-directed mutagenesis to create Flag-Exo1a, which
was 46 amino acids shorter. Mutation of Asp514 and
Asp78 to Ala was carried out by site-directed mutagenesis.
Expression constructs were transfected into cells using
Lipofectamine 2000
TM (Invitrogen) as per manufacturers
instructions, samples were assayed 24h after transfection.
siRNA
Stealth
TM Exo1 (UAGUGUUUCAGGAUCAACAUCA
UCU) and control siRNA was purchased from
Invitrogen. The siRNA was transfected into Hela cells
using Lipofectamine 2000
TM (Invitrogen) as per manufac-
turers instructions and samples were analysed 48h after
transfection.
Immunoblotting
The media was removed from Hela or MEF cells cultured
in 10cm tissue culture plates and replaced with 2ml of
PBS. Cells were then exposed to 40J/m
2 UVC (BioRad
Stratalinker), 100mM etoposide, 10mM actinomycin D
and incubated for the indicated times. Following incuba-
tion cells were scraped from tissue culture plates and
washed once in PBS. Cells were lysed (lysis buﬀer:
20mM Hepes pH 8, 150mM KCl, 5% glycerol, 10mM
MgCl2, 0.5mM EDTA, 0.02% NP-40, before use buﬀer
was supplemented with NaF, NaVO4, PMSF and protease
inhibitors) and sonicated. Lysates were cleared by centri-
fugation and protein concentrations were estimated using
the standard Bradford assay (Bradford reagent supplied
by Bio-Rad). Typically 50mg of protein lysate was sepa-
rated on a 4–12% sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS–PAGE) gel (Invitrogen) and
immunoblotted with the indicated antibodies.
Immunoprecipitation
Cells were treated and lysed as for immunoblotting.
Following cell lysis, lysates were diluted in 600ml of lysis
buﬀer and pre-cleared with 100ml sepharose. The lysate
was transferred to a new tube, to which 20ml (total
volume) of anti-FlagM2 beads (Sigma) were added.
Lysates were incubated with beads for at least 2h. Beads
were then washed 3–4 times with lysis buﬀer. Loading
buﬀer containing 10% b-mercaptoethanol was then
added to bead pellets and samples were boiled for 5min.
Samples were analysed via immunoblotting (as above).
Cytochrome c staining (fluorescence activated cell sorting
and immunofluorescence)
MEFs were grown at a density of 1 10
6, treated with
40J/m
2 UVC and incubated for 14h. Cytochrome c
release was measured using an InnoCyte
TM Flow
Cytometric Cytochrome c Release Kit (Calbiochem),
according to the manufacturers instructions.
Annexin V assay
Hela or MEF cells were treated with UVC, 1mM
staurosporine or 10mM actinomycin D as indicated
to induce apoptosis. Following incubation, all cells
(including ﬂoating ones) were trypsinized, washed once
in PBS and resuspended in 100ml 1X annexin V binding
buﬀer (10mM HEPES, 140mM NaCl and 2.5mM CaCl2
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Probes) and 1ml propidium iodide (1mg/ml) were added
to cells and incubated for 20min. Following incubation
400ml of 1X Annexin V binding buﬀer was added and
cells were analysed by ﬂuorescence activated cell sorting
(FACS). Cells positive for Annexin V were scored as
apoptotic.
In vitro caspase assay
Hela cells were transfected with the Flag-Exo1b wild-type
or Flag-Exo1b D514A constructs. Cell pellets were taken
and lysed (as for immunoblotting) 24h after transfection.
The 100mg of protein lysate was added to 20ml of caspase
activity buﬀer (6mM Tris–Cl pH7.5, 1.2mM CaCl2,
5mM DTT, 1.5mM MgCl2 and 1mM KCl) containing
three units of recombinant caspase-3 (cat # PH20014,
Biosource). Where indicated 20mM ZVAD-FMK was
added. Samples were incubated for 1h at 378C.
Following incubation samples were boiled in 10ml SDS
loading dye (Invitrogen). Samples were immunoblotted
as described above.
Immunofluorescence
Hela cells were seeded onto coverslips the day before
siRNA transfection. Following siRNA transfection, cells
were allowed to grow for 48h before treatment with
40J/m
2 UVC. After UVC treatment, cells were treated
with an extraction buﬀer (22) for 10min before ﬁxation
in 4% paraformaldehyde (PFA). Cells were permeabilized
with 0.2% Triton-X for 5min and blocked in 3% bovine
serum albumin (BSA) for 30min. Cells were incubated
with monoclonal RPA antibodies (Neomarkers) and
alexia-conjugated secondary antibodies for 1h each at
room temperature. Cells were stained with DAPI before
mounting onto slides. Cells containing over 20 foci were
scored as positive for RPA foci.
Terminal deoxynucleotidyl transferase dUTP nick end
labeling assay
Hela cells were grown on coverslips and transfected with
the indicated siRNA or plasmids. Cells were treated with
40J/m
2 UVC to induce apoptosis after 24 (plasmids) or
48h (siRNA) transfection. At the indicated time-point,
cells were ﬁxed in 4% paraformaldehyde. Terminal deox-
ynucleotidyl transferase dUTP nick end labeling
(TUNEL) staining was carried out using a Click-iT
TUNEL Alexa Fluor Imaging Assay (Invitrogen) as per
the manufacturers instructions. In each condition, 200
cells were scored for TUNEL staining.
RESULTS
Exo1 depletion confers resistance to apoptosis
Exo1 is known to function in many types of DNA damage
repair, however, the role of Exo1 in apoptosis remains
to be elucidated. Since other MMR proteins are required
for UV-induced apoptosis, we initially sought to investi-
gate whether Exo1 has a role in apoptosis (23,24).
Treatment of Hela cells with 40J/m
2 UVC was shown to
induce apoptosis rapidly as measured by the cleavage of
poly-ADP-polymerase (PARP1), a well characterized
apoptotic substrate of caspase-3 (Figure 1A). It was fur-
ther conﬁrmed that these conditions induced apoptosis by
annexin V analysis (Figure 1B). Hela cells were depleted of
Exo1 using siRNA, which targets the mRNA of both iso-
forms of Exo1 (Exo1a and Exo1b) and exposed to UVC.
The siRNA induced silencing of Exo1 reduced the protein
level as evident by the disappearance of  100kDa
band recognized by the Exo1 antibody (Figure 1C).
Interestingly, we also found signiﬁcant reduction in
Exo1 expression in control siRNA transfected cells after
exposure of cells to UVC, suggesting that Exo1 might
itself be targeted during apoptosis. The basis and signiﬁ-
cance of this degradation has been pursued in the latter
part of the manuscript.
Next, we examined apoptosis induction in Exo1 deﬁ-
cient cells. Given that pro-caspase-3 cleavage is required
for caspase-3 to become active and cleave its substrates,
we examined pro-caspase-3 cleavage in Exo1 deﬁcient
cells. We observed that caspase-3 was cleaved within
4h of exposure of control siRNA-transfected cells
to UVC, however, caspase-3 cleavage and subsequent
activation was suppressed in Exo1-deﬁcient cells
(Figure 1C). In order to further conﬁrm the apoptotic
defect in Exo1-deﬁcient cells the annexin V assay was
utilized. Cells transfected with control siRNA displayed
around 25% apoptosis 4h after treatment with 40J/m
2
UVC. In contrast, cells transfected with Exo1 siRNA
were markedly resistant to UV-induced apoptosis
and this resistance was characterized by a low percent-
age of annexin V positive cells that remained at
around 6% following UVC exposure (Figure 1D).
Camptothecin was also used to induce apoptosis and
similarly to UVC showed that Exo1-deﬁcient cells are
resistant to DNA damage-induced apoptosis (Supple-
mentary Figure 1).
Furthermore, we found that Exo1-deﬁcient MEFs (21)
showed a similar defect in pro-caspase-3 cleavage
(Figure 1E) and apoptosis defect, as measured by accumu-
lation of annexin V positive cells compared with wild-type
MEFs (Figure 1F). It should be noted that the Exo1 deﬁ-
cient MEFs used were also heterozygote for hMSH6.
MSH6 heterozygote MEFs do not display an apoptosis
defect (17). Overall, these data provide strong evidence
that Exo1 is required for the induction of DNA damage-
induced cell death/apoptosis.
Exo1 is required for cytochrome c release and DNA
fragmentation
During apoptosis, cytochrome c is released from the
mitochondria in response to a number of pro-apoptotic
stimuli. The release of cytochrome c leads to the activation
of caspases and progression of cell death (25). As deple-
tion of Exo1 prevented the activation of caspase-3
(Figure 1C and E), we next examined whether cytochrome
c was still released from the mitochondria in Exo1 deﬁ-
cient cells. Exo1 deﬁcient MEFs were treated with 40J/m
2
UVC and cytochrome c levels were measured via FACS
14h after treatment. In wild-type MEFs, the number
3454 Nucleic Acids Research, 2009, Vol. 37,No. 10of cytochrome c positive cells were reduced by around
40% following UVC treatment, whereas levels were only
reduced by around 5% in Exo1 deﬁcient MEFs
(Figure 2A and B), indicating that Exo1’s role in apoptosis
is upstream of cytochrome c release and subsequent cas-
pase activation.
During apoptosis, caspase-3 dependent DNA-
degradation occurs, executed by the CAD nuclease (26).
To examine whether Exo1 is required for DNA fragmen-
tation during apoptosis, we utilized TUNEL staining,
which speciﬁcally identiﬁes cells undergoing DNA frag-
mentation. Hela cells depleted of Exo1 with siRNA were
Figure 1. Exo1 is required for the induction of apoptosis. (A) Hela cells were treated with 40J/m
2 UVC and lysates were taken at the indicated time-
points for immunoblotting with the indicated antibodies. (B) Hela cells were treated as in (A), cells were harvested at the indicated times and
analysed for annexin V staining via FACS. (C) Hela cells were transfected with control or Exo1 siRNA before treatment with 40J/m
2 UVC. Lysates
were taken and immunoblotted with the indicated antibodies 6h after treatment. (D) Hela cells were treated as in (C) and stained with annexin V
antibodies 4h after the indicated dose of UVC. Cells were analysed for annexin V staining via FACS. (E) Wild-type and Exo1 deﬁcient MEFs were
treated with 40J/m
2 UVC, incubated for 8h and lysates immunoblotted with the indicated antibodies. (F) Wild-type and Exo1-deﬁcient MEFs were
treated with 40J/m
2 UVC and incubated for 8 or 16h before staining with annexin V antibodies and FACS analysis. For annexin V experiments, the
means and SD of three independent experiments are shown.
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DNA fragmentation (Figure 2C and D). Similar results
were also obtained in Exo1-deﬁcient MEFs (Supplemen-
tary Figure 2).
Exo1 is dispensable for other forms of apoptosis
Given the role of Exo1 in DNA damage repair, we rea-
soned that Exo1 may be required for apoptosis induced
speciﬁcally by DNA damage. We examined the extent
of apoptosis induced by staurosporine and actinomycin
D in Exo1 deﬁcient cells. Staurosporine (27) is an inhibitor
of protein kinase C and actinomycin D is an inhibitor
of mRNA synthesis (28), but neither cause DNA
damage. Like UVC, both staurosporine and actinomycin
D induce apoptosis via the caspase-3 pathway. Exo1 deﬁ-
cient MEFs were found to be as sensitive as wild-type
MEFs to treatment with staurosporine or actinomycin D
as measured by annexin V assay (Figure 3A and B) and
PARP1 cleavage (Figure 3C). These data indicate that
Exo1 is required for DNA damage-induced apoptosis
but is not universally required for caspase-3 activation.
Depletion of Exo1 does not disrupt UV-induced
ATR-mediated pathways
The above data suggests Exo1 is a diﬀerential regulator
of apoptosis depending on the type of cellular insult and
may have a role upstream of both caspase-3 and PARP1
cleavage in response to UV-induced apoptosis This raises
the possibility that Exo1 acts as a DNA damage sensor to
induce apoptosis.
Following DNA damage primary lesions are often pro-
cessed by nucleases that generate single-stranded DNA
(ssDNA), which is believed to play a key function in the
DNA damage response. The major kinase involved in
the checkpoint response to UV-induced DNA damage
is Ataxia Telangiectasia mutated and Rad3 related
Figure 2. Exo1 is required for cytochrome c release. (A) Wild-type and Exo1 deﬁcient MEFs were treated with 40J/m
2 UVC and incubated for 14h.
Cells were ﬁxed and incubated with a cytochrome c antibody before FACS analysis was carried out. (B) Cells were treated as in (A) and subjected to
immunoﬂuorescence. Representative images are shown. (C) Hela cells were grown on coverslips and transfected with the indicated siRNAs. Cells
were treated with 40J/m
2 UVC after 48h transfection. Cells were ﬁxed and subjected to TUNEL staining after 4 or 6h treatment. For TUNEL
staining, 200 cells were scored. The results presented are the average of three independent experiments and the error bars represent the SD. (D)
Representative images of C.
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ATR has a role in UVC-induced apoptosis (9), we next
examined whether Exo1b is required for the ATR-
mediated UV-response. ATR mediated signalling prefer-
entially triggers the phosphorylation and activation of the
Chk1 kinase after UV. Exo1-depleted Hela cells were
found to have a similar level of Chk1 phosphorylation
as control cells following UVC treatment (Figure 4A).
In addition, ATR levels were not altered in Exo1
depleted cells (Figure 4A). Since phosphorylation of
p53 on serine 15 in humans (30) and serine 18 in mice
(31) has been shown to be required for induction of apop-
tosis we next sought to examine p53 phosphorylation.
Exo1 deﬁcient MEFs were found to have comparable
p53 serine 18 phosphorylation to wild-type MEFs fol-
lowing UVC treatment (Figure 4B), suggesting that the
inhibition of apoptosis in Exo1-deﬁcient cells is p53
independent.
Following DNA damage by agents such as UVC many
repair proteins localize to nuclear foci, marking the sites of
DNA damage. RPA is a single stranded DNA binding
protein involved in many forms of DNA repair and is
known to coat long stretches of ssDNA generated after
the processing of primary DNA lesions. RPA localizes to
these sites of DNA damage after UVC treatment in an
ATR-dependent manner, so we next decided to examine
whether RPA localized correctly in the absence of Exo1.
We observed that RPA foci formation was not aﬀected
by the lack of Exo1 in Exo1-deﬁcient MEFs (Figure 4C
and D), indicating an Exo1-independent mechanism pro-
cesses primary UV-induced lesions and activates the ATR
pathway.
Cleavage of Exo1 during apoptosis
During the course of above studies, we noticed that
Exo1 was degraded in normal/wild-type cells undergoing
apoptosis (Figure 1C) and given the resistance of
Exo1-deﬁcient cells to apoptosis, we next investigated
whether cleavage of Exo1 is required to activate the apop-
totic pathway. To determine the fate of Exo1 during
UV-induced apoptosis, we transfected Hela cells with
GFP-Exo1b and treated with UVC. We detected a protein
mobility shift of Exo1b within 1h of exposure to UV,
which was shown to be due to phosphorylation, as
lambda phosphatase treatment prevented the shift
(Figure 5A). As mentioned previously (32), Exo1b is dif-
ﬁcult to detect in human cells due to a low abundance of
protein and the lack of high aﬃnity antibodies. We found
that in 100mg of nuclear lysates endogenous Exo1b
could be detected via immunoblotting and at 6h after
UVC treatment Exo1b levels were signiﬁcantly depleted
(Figures 5B and 1C). In agreement with this, an
exogenous Flag-tagged Exo1b driven by a heterologous
promoter was reduced in levels in a time-dependent
Figure 3. Exo1 is dispensable for other forms of apoptosis. (A) Wild-type and Exo1-deﬁcient MEFs were treated with 1mM staurosporine and
incubated for 6h before staining with annexin V antibodies and FACS analysis. The means and SD of two independent experiments are shown. (B)
Wild-type and Exo1-deﬁcient MEFs were treated with 10mM actinomycin D or 40J/m
2 UVC and incubated for the indicated times before staining
with annexin V antibodies and FACS analysis. The means and SD of three independent experiments are shown. (C) Wild-type and Exo1 deﬁcient
MEFs were treated with 40J/m
2 UVC or 10mM actinomycin D, incubated for the indicated times and lysates were immunoblotted with the indicated
antibodies.
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in full length Exo1b, we observed the appearance of a
60kDa polypeptide speciﬁcally recognized by anti-Flag
antibody in cells expressing Flag-Exo1b (Figure 5C).
Since the Flag-tag is localized on the N-terminus of this
fusion protein, we postulated that the fragment generated
comprised the N-terminus of Exo1. This band was subse-
quently analysed by Matrix Assisted Laser Desorption
Ionisation-Time of Flight-mass spectrometry (MALDI-
TOF-MS) and was conﬁrmed to be Exo1b (data not
shown). The other isoform of Exo1, Exo1a was also
degraded following UVC treatment, producing an approx-
imately 60kDa fragment (Supplementary Figure 3). For
the rest of our investigation, we have focused on the
longer isoform, Exo1b as this is the more extensively stud-
ied and therefore best characterized isoform.
Since the doses of UVC used earlier in this investigation
were shown to induce apoptosis (Figure 1A and B) we
concluded that the degradation of Exo1 was a result of
the apoptotic process. The degradation of Exo1 paralleled
the extent of apoptosis induction as evident by annexin
V positive cells, which increased in a time-dependent
manner following UVC treatment. In addition, the
cleavage of Exo1 coincided with the cleavage of PARP1
(33), a well-characterized substrate of caspase-3, in a time-
dependent manner following UVC treatment (Figures 1A
and 5D).
The cleavage of Exo1 was speciﬁc to apoptosis as no
degradation was observed in Hela cells treated with ionis-
ing radiation (IR) (10Gy) (Figure 5D). IR fails to induce
apoptosis in Hela cells at this dose as demonstrated by
the lack of cleavage of PARP1 for up to 6h post-IR treat-
ment. In addition, the speciﬁc cleavage of both Exo1
and PARP1 was evident in Hela cells exposed to other
agents, including etoposide, shown previously to induce
apoptosis in these cells (Figure 5E), indicating that Exo1
cleavage is correlated with apoptosis.
Cleavage of Exo1b is mediated by caspase-3 during
apoptosis
Given that caspases are the main proteases responsible
for proteolysis during apoptosis, we next examined
whether Exo1b cleavage is dependent upon this group of
proteins. We initially employed a broad-spectrum caspase
inhibitor, ZVAD-FMK, to study the requirement of cas-
pases in Exo1 cleavage during apoptosis. The presence of
Figure 4. Depletion of Exo1 does not disrupt UV-induced ATR-mediated pathways. (A) Hela cells were transfected with the indicated siRNAs,
treated with 40J/m
2 UVC and extracts taken 2h after treatment for immunoblotting with the indicated antibodies. (B) Wild-type and Exo1 deﬁcient
MEFs were treated as in (A), and immunoblotted with p53 serine 15 antibodies (which detect phosphorylation on serine 18 in MEFs). (C) Wild-type
and Exo1 deﬁcient MEFs were treated as in (A), and stained with monoclonal RPA antibodies. (D) Graphical representation of the percentage of
MEF cells positive for RPA foci in three independent experiments. The error bars represent the SD.
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UVC-induced apoptosis (Figure 6A). The ZVAD-FMK
inhibitor also protected the caspase-3 substrate PARP1
from cleavage following UVC-treatment, suggesting
that caspase-3 may be the protease required for Exo1b
cleavage.
To provide direct evidence for the involve-
ment of caspase-3 in Exo1b cleavage, recombinant
caspase-3 was added to lysates containing Flag-Exo1b.
Following incubation with caspase-3, lysates were
immunoblotted with anti-Flag antibodies. While predomi-
nantly full length Exo1b could be detected in the
absence of caspase-3, the lysates incubated with recom-
binant caspase-3 contained predominantly cleaved
Exo1b (Figure 6B). PARP1 was also cleaved in these
lysates showing caspase-3 cleavage speciﬁcity. As antici-
pated, the presence of the ZVAD-FMK caspase inhibitor
prevented the caspase-mediated cleavage of both Exo1b
and PARP1.
Identification of the caspase-3 cleavage site in Exo1b
Caspase-3 recognizes the DXXD motif in its substrates
and cleaves immediately following this site (34). Analysis
of the Exo1b amino acid sequence led to identiﬁcation of
a putative caspase-3 cleavage site, DSTD
514 (Figure 6C).
We predicted that cleavage of Exo1b at this site would
give rise to a N-terminal fragment of around 60kDa,
which is consistent with the size of the cleaved Exo1b
fragment observed during apoptosis. In order to conﬁrm
this motif as a genuine caspase-3 cleavage site we gener-
ated a Flag-Exo1b fusion protein containing a mutation of
the aspartic acid amino acid at position 514 to alanine
(11). Plasmids expressing the mutant and wild-type pro-
teins were transiently transfected into Hela cells. Lysates
containing the mutant protein were prepared and incu-
bated with recombinant caspase-3 and immunoblotted.
In contrast to the wild-type protein, the D514A mutant
was not degraded by recombinant caspase-3 (Figure 6D).
Figure 5. Distinct fates of Exo1b following DNA damage. Unless otherwise stated, Hela cells were treated or mock-treated with 40J/m
2 UVC. (A)
Hela cells were transiently transfected with GFP-Exo1b, treated with UVC and lysates taken 1h after treatment for immunoblotting with the
indicated antibodies. Lysates were incubated with llambda phosphatase where indicated. (B) Hela cells were treated with UVC and extracts taken for
immunoblotting 6h after treatment. (C) Hela cells were transfected with Flag or Flag-Exo1b, treated with UVC and extracts were taken at the
indicated time-points. Immunoprecipitations were carried out using Flag M2 beads and immunoblotted with the Flag antibody. The panel to the left
shows the protein molecular weight markers. (D) Hela cells were treated with 40J/m
2 UVC or 10Gy IR and lysates taken for immunoprecipitation
and immunoblotting at the indicated times. (E) Hela cells were treated with 100mM ETOP, extracts taken and immunoprecipitated with Flag M2.
Immunoprecipitations were immunoblotted with the indicated antibodies. Arrowheads denote cleaved Exo1b. Asterisk indicates non-speciﬁc cross-
reacting bands.
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caspase-3 target site. PARP1 cleavage was also analysed
as a positive control and was still cleaved in the lysates
containing D514A.
The effect of over-expression of an Exo1 fragment or
cleavage-resistant Exo1 on apoptosis
Cleavage of proteins during apoptosis sometimes leads,
as in the case of other DNA repair proteins such as
hMLH1 (24) and Claspin (35) to fragments that have
dominant-negative activity. Such fragments appear to
have pro-apoptotic roles in the progression of this type
of cell death. Since the N-terminal fragment generated
during apoptosis contains the nuclease domain of Exo1,
this prompted us to speculate that the nuclease activity
of cleaved-Exo1 may have a role in DNA degradation
during apoptosis. This hypothesis is based on an earlier
report that demonstrated that a fragment of Exo1 contain-
ing amino acids 1–391 was proﬁcient in 50-30 nuclease
activity (11). The fragment generated during apoptosis
in the current study contains amino acids 1–514 of
Exo1 and in light of the above it seems likely that this
fragment will retain nuclease and DNA binding activity.
Therefore, we tested the eﬀect of over-expression of this
fragment (1–514) and degradation-resistant (D514A)
full length Exo1b on DNA damage-induced apoptosis in
Hela cells in comparison with wild-type and nuclease-
deﬁcient (D78A) Exo1b. Expression of these constructs
in Hela cells in the absence or presence of UVC had
very little eﬀect on the levels of apoptosis as assessed by
cleavage of PARP1 (Supplementary Figure 4) or annexin
V staining (Supplementary Figure 5B). Expression of
these constructs also had no signiﬁcant eﬀect on DNA
fragmentation, as measured by TUNEL staining
(Supplementary Figure 5C).
DISCUSSION
Apoptosis is a fundamentally important cellular process,
which orchestrates a series of controlled events, which
ultimately leads to cell death. Apoptosis exists solely in
multi-cellular organisms where it protects the organism
from the accumulation of deleterious DNA mutations,
which could result in loss of cellular programming.
Speciﬁc DNA repair proteins such as, MLH1 (24),
MSH2 (36) ATR and ATM (9) have been shown to
have a role in the induction of apoptosis. Since Exo1 is
known to be involved in DNA repair and interacts with
other MMR proteins we examined whether Exo1 itself has
a role in apoptosis. Here, we provide for the ﬁrst time a
role for the evolutionary conserved exonuclease, Exo1b, in
UV-induced apoptosis.
Using Exo1-deﬁcient MEFs and Hela cells, we found
that Exo1 was required for timely, UVC-induced apopto-
sis. We further show that Exo1 deﬁcient cells do not
release cytochrome c from the mitochondria and both
caspase-3 activation and PARP1 cleavage are absent fol-
lowing the induction of apoptosis by UVC. To elucidate
the function of Exo1 in this process, we examined the
Figure 6. Caspase-3 cleaves Exo1 during apoptosis. Hela cells were transiently transfected with the indicated constructs. (A) Hela cells were mock-
treated or pre-treated with ZVAD-FMK for 1h, before being treated with 40J/m
2 UVC. Lysates were taken for immunoprecipitation with Flag M2
beads and immunoblotting 6h after UVC treatment. (B) Hela lysates were incubated with 3U of recombinant caspase-3 at 378C in the presence or
absence of ZVAD-FMK before immunoblotting with the indicated antibodies. (C) Schematic diagram of Exo1b showing putative caspase-3 cleavage
site, D514A. (D) Hela lysates containing either Flag-Exo1b wild-type or D514A were incubated with 3U of recombinant caspase-3 at 378C in the
presence or absence of ZVAD-FMK before immunoblotting with the indicated antibodies. Arrowheads denote cleaved Exo1b. Asterisk indicates
non-speciﬁc cross-reacting bands.
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(9). It has been previously shown that ATR is required for
apoptosis following UVC-treatment (9). We have shown
here that Exo1 must function downstream or in a diﬀerent
pathway from ATR as depletion of Exo1 did not aﬀect the
phosphorylation or the localization of key ATR target
proteins. This is consistent with a recent study in which
Exo1 depletion had little impact on ATR signalling (37).
Furthermore, we have shown here that p53 is unlikely to
be involved in Exo1-mediated apoptosis as Exo1-deﬁcient
MEF cells can still phosphorylate p53 on serine 18. The
Exo1-mediated apoptosis documented here is therefore
downstream of or independent of ATR and p53 and sug-
gests the involvement of other signalling pathways.
There is increasing evidence that polymorphisms in
Exo1 may be associated with colorectal and lung cancer
occurrence (19,20,38). Some of these polymorphisms have
been shown to disrupt the interactions between Exo1,
hMLH1 and hMSH2 and therefore inhibit MMR (20).
It is possible that these polymorphisms may also disrupt
the role of Exo1 and other MMR proteins in apoptosis.
Thus such polymorphisms may not only compromise
DNA repair but promote tumour cell survival via an
apoptotic defect, especially in environments where DNA
damage may accumulate, such as the colon or lungs.
The key eﬀectors in apoptosis are the caspase proteases,
a group of proteins that function by cleaving speciﬁc pro-
teins at conserved sites this results in either the activation
or inactivation of their substrates. In order to dissect the
downstream events of apoptosis, it is of fundamental
importance to identify the substrates of the eﬀector cas-
pases. In addition to Exo1 acting upstream of caspases in
the induction of UV-induced apoptosis, we also noticed
that Exo1 was cleaved during apoptosis. The fate of the
Exo1b isoform, following DNA damage-induced apopto-
sis, was found to be time-dependant. Initially, Exo1b is
phosphorylated following UVC treatment, however 2h
after treatment the levels of full length Exo1b decreased
with the concomitant generation of a smaller, stable
60kDa Exo1b fragment. This cleavage of Exo1b corre-
lated with the induction of apoptosis. Previous work in
both lower and higher eukaryotic systems has provided
evidence for the involvement of Exo1 in several types
of DNA repair (11,12,15,39). In light of the above, it is
notable that the cleavage of Exo1 mimics that of other
DNA repair proteins including PARP1 (33), ATM (7),
DNAPKcs (8), BRCA1 (40), MLH1 (24) and Rad51
(41). The low abundance of Exo1b protein in mammalian
cells may provide an explanation as to why Exo1 has
remained undiscovered as a caspase substrate for so long.
Since Exo1 was cleaved during apoptosis, it was pre-
dicted that caspases would be the most likely eﬀector of
such an event and indeed we have mapped the site of Exo1
cleavage to Asp514 (DXXD caspase 3 consensus site) and
found this event to be directly mediated by the caspase
3 protease.
Since DNA is fragmented during apoptosis and Exo1 is
a nuclease it is tempting to speculate that Exo1 has a role
in degrading DNA during apoptosis. We consider this
implication unlikely when we compare it with the major
apoptotic nuclease CAD for a number of reasons. First,
CAD is expressed in the cytoplasm and once cleaved by
caspase-3 translocates into the nuclease and degrades
DNA (5,6). In contrast Exo1b is predominantly found
in the nucleus and its localization does not change
during apoptosis (Bolderson and Khanna, unpublished
data). In addition, CAD has been shown to function
solely downstream of caspase-3 activation, while we
have shown Exo1 to have an essential apoptotic function
upstream of caspase-3 (5,6). Although we have shown that
Exo1-deﬁcient cells are resistant to apoptotic DNA-frag-
mentation, this is not unexpected as we have also shown
that Exo1 inhibits caspase-3 activation and caspase-3
activity is required for DNA fragmentation (26).
Over-expression of the full length Exo1b, cleavage-
resistant Exo1b (D514A), nuclease deﬁcient Exo1b
(D78A) or the caspase-3 cleaved Exo1 fragment (amino
acids 1–514) did not aﬀect the induction of apoptosis as
measured by PARP1 cleavage or annexin V. In addition,
expression of these constructs had no signiﬁcant aﬀect on
the induction of DNA fragmentation during apoptosis, as
measured by TUNEL staining. Taken together, these data
suggest that depletion of Exo1 inhibits DNA fragmenta-
tion during apoptosis via a caspase-3 dependent mecha-
nism. In addition, we conclude that the fragment of
Exo1b produced during apoptosis is not likely to be pro-
apoptotic. However, it is possible that unlike other DNA
repair proteins (24,40) the presence of the Exo1 cleavage
fragment alone is not suﬃcient to stimulate apoptosis and
that the proteolysis of other apoptotic factors is also
required.
Given the upstream role for Exo1 in the induction of
apoptosis, it is thus likely that the presence of the full
length wild-type Exo1 protein is required for the induction
of apoptosis, but only in the presence of DNA damage
stimuli such as UVC. Exo1 is then subsequently cleaved to
allow cells to undergo apoptosis eﬃciently by preventing
the repair of fragmented DNA.
The potential function of Exo1 in DNA repair suggests
that its cleavage may compromise its repair function by
preventing it from participating in the repair of DNA
damage such as DNA breaks generated by CAD (5,6).
Following Caspase-3 cleavage PARP1 (33) and ATM (7)
also retain their DNA-binding ability and it has been sug-
gested that these inactive proteins may bind to the frag-
mented DNA and prevent DNA damage repair signaling.
Together, these ﬁndings led us to speculate that Exo1
plays a crucial role in initially contributing to the induc-
tion of apoptosis and once apoptosis commences it is
functionally inactivated by caspase 3 cleavage.
In summary, these results suggest that the full length
Exo1 is required for induction of apoptosis, possibly via
a role in a DNA damage-sensing complex. Our ﬁnding
that Exo1 is speciﬁcally cleaved in cells undergoing apop-
tosis supports the hypothesis that a function of the eﬀector
caspases is to disassemble proteins that can repair the
DNA and thus allow apoptosis to proceed.
SUPPLEMENTARY DATA
Supplementary Data is available at NAR Online
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